Truist Financial Corp trimmed its holdings in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 29.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,303 shares of the company’s stock after selling 3,878 shares during the quarter. Truist Financial Corp’s holdings in DaVita were worth $770,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in DVA. ACG Wealth bought a new stake in shares of DaVita during the second quarter worth $28,000. Parkside Financial Bank & Trust raised its holdings in shares of DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock valued at $35,000 after acquiring an additional 147 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of DaVita in the third quarter valued at about $44,000. CWM LLC raised its holdings in shares of DaVita by 38.0% in the second quarter. CWM LLC now owns 596 shares of the company’s stock valued at $48,000 after acquiring an additional 164 shares in the last quarter. Finally, AIA Group Ltd bought a new stake in shares of DaVita in the second quarter valued at about $51,000. 86.52% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently weighed in on DVA. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a report on Friday, December 9th. UBS Group downgraded DaVita from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $117.00 to $74.00 in a report on Monday, October 31st. Barclays cut their target price on DaVita from $103.00 to $81.00 and set an “equal weight” rating on the stock in a research note on Monday, October 31st. TheStreet lowered DaVita from a “b-” rating to a “c+” rating in a research note on Tuesday, November 1st. Finally, Truist Financial cut their target price on DaVita from $90.00 to $75.00 and set a “hold” rating on the stock in a research note on Monday, October 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $81.17.
Insider Activity at DaVita
DaVita Price Performance
Shares of DVA stock opened at $80.32 on Friday. DaVita Inc. has a fifty-two week low of $65.28 and a fifty-two week high of $124.81. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 11.76, a PEG ratio of 1.45 and a beta of 0.96. The company has a debt-to-equity ratio of 12.63, a quick ratio of 1.22 and a current ratio of 1.26. The stock’s 50-day simple moving average is $74.65 and its 200-day simple moving average is $82.19.
DaVita (NYSE:DVA – Get Rating) last issued its quarterly earnings results on Friday, October 28th. The company reported $1.45 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.20). DaVita had a return on equity of 85.60% and a net margin of 5.84%. The business had revenue of $2.95 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the previous year, the firm posted $2.36 EPS. DaVita’s revenue was up .4% on a year-over-year basis. As a group, equities analysts forecast that DaVita Inc. will post 6.32 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.